#USA #Mahwah #Glenmark #Latanoprost #Ophthalmic Solutions

Glenmark Pharmaceuticals Unveils Latanoprost Ophthalmic Solution

Glenmark Pharmaceuticals Inc., USA, has recently announced the launch of its new product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). This new addition is bioequivalent and therapeutically equivalent to the established reference drug, Xalatan® Ophthalmic Solution, 0.005%, developed by Upjohn US 2 LLC. The introduction of Glenmark's Latanoprost marks a significant expansion in the company’s ophthalmic portfolio, showcasing its dedication to enhancing treatment options for patients suffering from ocular conditions.

Market Overview

Recent data from IQVIA™ indicates that the market for Xalatan® Ophthalmic Solution, 0.005% reached a remarkable annual sales figure of approximately $113.5 million for the 12-month period ending December 2024. This underscores the robust demand for effective ophthalmic solutions, which Glenmark aims to fulfill with its newly launched product.

Marc Kikuchi, President and Business Head for North America at Glenmark, expressed excitement about the release, stating, "We are thrilled to introduce our fourth ophthalmic product, Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL). This launch not only enhances our product offerings in the ophthalmic sector but also demonstrates our commitment to addressing market needs and providing high-quality solutions for our customers."

About Glenmark Pharmaceuticals

Established as a research-focused global pharmaceutical entity, Glenmark Pharmaceuticals Ltd. operates across various segments, including branded drugs, generics, and over-the-counter products. The organization emphasizes therapeutic areas such as respiratory, dermatology, and oncology. With 11 manufacturing facilities located across four continents and operations in over 80 countries, the company is recognized as one of the top biopharmaceutical companies globally. Glenmark secured its place in the Scrip 100 list due to its impressive pharmaceutical sales and ranked among the top 50 generics and biosimilar companies by sales in 2024.

Commitment to Environmental Sustainability

In addition to its business achievements, Glenmark has set ambitious goals for reducing greenhouse gas (GHG) emissions, which have been endorsed by the Science Based Targets initiative (SBTi). This recognition makes Glenmark the second pharmaceutical company in India to achieve such an accolade, demonstrating its commitment to sustainable practices.

Furthermore, over the last decade, Glenmark has positively impacted more than 3.3 million lives through its various corporate social responsibility initiatives, which focus on improving health and well-being in the community.

For more information about Glenmark and its commitment to innovative healthcare solutions, you can visit their official website at www.glenmarkpharma.com or follow them on social media platforms such as LinkedIn and Instagram.

Conclusion

With the introduction of Latanoprost Ophthalmic Solution, Glenmark Pharmaceuticals continues to strengthen its presence in the ophthalmic market while remaining committed to environmental sustainability and impactful community initiatives. This new product not only broadens their portfolio but also reinforces their dedication to delivering quality healthcare solutions to patients.